CagriSema (cagrilintide + semaglutide)
Under FDA review for weight management; the company expects a decision in late 2026.
What it is
Once-weekly combination of semaglutide and the amylin analogue cagrilintide for weight management. It is the company's main bet on a next-generation obesity drug.
Why it matters to the stock. CagriSema is the main pipeline catalyst to watch for future obesity growth. A US approval would extend the company's lead, and a rejection would hit the long-term outlook.
News
CagriSema beats tirzepatide 5 mg on weight in REIMAGINE 5 and 21% weight loss in REDEFINE 9
Novo reported topline phase 3 results for CagriSema on 21 September 2026.
Novo to present 44 abstracts at EASD 2026 including Wegovy pill real-world data
Novo said it will present 44 abstracts at the EASD 2026 diabetes meeting in Milan from 28 September to 2 October, covering semaglutide, CagriSema and zenagamtide.
CagriSema matches tirzepatide on weight but misses HbA1c non-inferiority
In the 68-week open-label REIMAGINE 4 trial in adults with type 2 diabetes, CagriSema 2.4/2.4 mg was non-inferior to tirzepatide 15 mg for weight reduction but not for HbA1c reduction.
CagriSema diabetes trials REIMAGINE 1-3 show HbA1c and weight reductions at ADA 2026
Novo Nordisk presented REIMAGINE 1 to 3 data for CagriSema 2.4 mg/2.4 mg in type 2 diabetes at the ADA Scientific Sessions in New Orleans, June 5 to 8, 2026.
CagriSema fails non-inferiority versus tirzepatide in head-to-head REDEFINE 4
In the open-label REDEFINE 4 trial, CagriSema produced 23.0% weight loss at 84 weeks on the adherent-patient measure, against 25.5% for tirzepatide 15 mg from Eli Lilly.